Lipocine Management
Management criteria checks 3/4
Lipocine's CEO is Mahesh Patel, appointed in Jan 1997, has a tenure of 27.92 years. total yearly compensation is $860.34K, comprised of 61% salary and 39% bonuses, including company stock and options. directly owns 2.01% of the company’s shares, worth $523.13K. The average tenure of the management team and the board of directors is 7.1 years and 10.9 years respectively.
Key information
Mahesh Patel
Chief executive officer
US$860.3k
Total compensation
CEO salary percentage | 61.0% |
CEO tenure | 27.9yrs |
CEO ownership | 2.0% |
Management average tenure | 7.1yrs |
Board average tenure | 10.9yrs |
Recent management updates
Recent updates
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
Sep 26Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression
Jun 14Lipocine competitor prevails in patent infringement lawsuit for Jatenzo
May 26When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?
May 11Lipocine EPS beats by $0.01
May 06Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?
Jan 26Lipocine announces positive results from phase 2biopsy-confirmed NASH study
Jan 12FDA Ok's Lipocine's testosterone replacement therapy, tentatively
Dec 09Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04Lipocine EPS misses by $0.01
Nov 10Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
Nov 06CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$4m |
Jun 30 2024 | n/a | n/a | -US$8m |
Mar 31 2024 | n/a | n/a | -US$9m |
Dec 31 2023 | US$860k | US$525k | -US$16m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$12m |
Mar 31 2023 | n/a | n/a | -US$11m |
Dec 31 2022 | US$884k | US$494k | -US$11m |
Sep 30 2022 | n/a | n/a | US$4m |
Jun 30 2022 | n/a | n/a | US$3m |
Mar 31 2022 | n/a | n/a | -US$754k |
Dec 31 2021 | US$1m | US$471k | -US$634k |
Sep 30 2021 | n/a | n/a | -US$18m |
Jun 30 2021 | n/a | n/a | -US$19m |
Mar 31 2021 | n/a | n/a | -US$19m |
Dec 31 2020 | US$994k | US$457k | -US$21m |
Sep 30 2020 | n/a | n/a | -US$20m |
Jun 30 2020 | n/a | n/a | -US$18m |
Mar 31 2020 | n/a | n/a | -US$16m |
Dec 31 2019 | US$521k | US$457k | -US$13m |
Sep 30 2019 | n/a | n/a | -US$13m |
Jun 30 2019 | n/a | n/a | -US$12m |
Mar 31 2019 | n/a | n/a | -US$12m |
Dec 31 2018 | US$1m | US$439k | -US$12m |
Sep 30 2018 | n/a | n/a | -US$14m |
Jun 30 2018 | n/a | n/a | -US$16m |
Mar 31 2018 | n/a | n/a | -US$19m |
Dec 31 2017 | US$1m | US$435k | -US$21m |
Compensation vs Market: Mahesh's total compensation ($USD860.34K) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Mahesh's compensation has been consistent with company performance over the past year.
CEO
Mahesh Patel (67 yo)
27.9yrs
Tenure
US$860,343
Compensation
Dr. Mahesh V. Patel, Ph D., co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997 and serves as its Interim Principal Financial Officer since January 31, 2...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 27.9yrs | US$860.34k | 2.01% $ 523.1k | |
Principal Accounting Officer & Corporate Controller | 6.2yrs | US$321.07k | 0.014% $ 3.6k | |
Senior Vice President of Research & Development | 2yrs | US$385.71k | 0.074% $ 19.2k | |
Vice President of Sales | 7.7yrs | US$633.01k | no data | |
Chief Medical Director | 7.1yrs | no data | no data |
7.1yrs
Average Tenure
56yo
Average Age
Experienced Management: LPCN's management team is seasoned and experienced (7.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 27.9yrs | US$860.34k | 2.01% $ 523.1k | |
Independent Director | 10.9yrs | US$75.03k | 0.016% $ 4.0k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 10.9yrs | US$79.66k | 0.0072% $ 1.9k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Director | 21.9yrs | US$62.28k | 0.76% $ 198.7k | |
Lead Independent Director & Chairman of the Board | 2.7yrs | US$91.91k | 0.024% $ 6.2k |
10.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: LPCN's board of directors are seasoned and experienced ( 10.9 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 05:06 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lipocine Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Scott Henry | Alliance Global Partners |
John Newman | Canaccord Genuity |
Corey Davis | Canaccord Genuity |